Fig. 11

In vitro, confirmation of differentially expressed protein (galectin-3) expression in MSC-conditioned medium treatment for NRK-49F (A, B) and NRK-52E (C, D) induced by human recombinant TGF-β1 (20 ng/mL) with or without galectin-3 inhibitor, TD139 (15 nmol/L) pretreatment by immunoblotting analysis. In vivo, confirmation of differentially expressed protein (galectin-3) by western blot (E, F) and Q-PCR (G) in adenine-induced kidney tissues post-MSC treatment. Q-PCR ratios, WB ratios, and iTRAQ ratios (adenine/adenine+MSCs) were shown on the H. The GAPDH protein was used as a control. Representative mRNA, representative immunoblotting, and densitometric analysis of galectin-3 expression in kidney tissues and cells. Results were normalized relative to the expression of GAPDH. N = 3 (per group). Data are presented as mean ± SD, and analyzed by one-way ANOVA followed by Bonferroni post hoc testing. *P < 0.05, vs. control group, ^#P < 0.05, vs. adenine group in kidney tissues; *^{, #}P < 0.05, vs. TGF-β1 group, ^△P < 0.05, vs. TGF-β1+TD139 group in NRK-49F cells; *^{, #}P < 0.05, vs. TGF-β1 group, ^△P < 0.05, vs. TGF-β1+MSC group in NRK-52E cells. Western blot analysis showed decreased levels of galectin-3 post-MSCs treatment in the adenine-induced rats and cells; TD139 pretreatment further reduced galectin-3 expression